RxDoctor Payments Data

Sileen Dowis, PA

Physician Assistant · Kansas City, MONPI 1326396904

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $83,140 of the $117,194 with a category attached, or 70.9%. 29 manufacturers reported payments, led by Dermavant Sciences, Inc. at 47.9% of the total. Among physician assistant clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$117,194in general payments, 2019–2025

Across 776 payments — averaging $151.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dermavant Sciences, Inc.$56K
  • Galderma Laboratories, L.p.$26K
  • Organon$24K
  • Regeneron Healthcare Solutions, Inc.$2K
  • AbbVie$2K
  • E.r. Squibb & Sons, L.L.C.$910
  • plus $7K from 23 others

What the payments were for

  • Consulting fees$1,0941%
  • Speaking & faculty fees$83,14071%
  • Travel & lodging$11,96510%
  • Food & beverage$20,22117%
  • Education$7741%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$117,194 in reported general payments places this provider in the 95th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$130,676
Medicare patients
609
Services billed
2,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab21$106,927
Dupixent SyringeDupilumab27$102,317
OtezlaApremilast20$94,396
Clobetasol Propionate105$6,355
Fluorouracil34$2,650
Metronidazole25$1,591
Triamcinolone Acetonide97$960
Ciclopirox20$869
Betamethasone Dipropionate15$711
Imiquimod23$610
Finasteride24$383
Hydroxyzine Hcl34$378
Minoxidil36$362
Doxycycline Hyclate15$235
Doxepin Hcl15$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$298$94,39620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →